Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
复制标题
DOI：
10.1080/14737140.2022.2096009
复制
发表时间：
2022-08-06
影响因子：
3.3
通讯作者：
Ghobadi, Armin
中科院分区：
文献类型：
--
作者：
Cohen, Jared A.;Ghobadi, Armin
简介Axicabagene cilleucel是一种自体抗CD19嵌合抗原受体(CAR)T细胞疗法，最近被批准用于复发或难治性滤泡性淋巴瘤，包括使用烷化剂的抗CD20单抗，为临床预后较差的惰性非霍奇金淋巴瘤亚群提供了治疗突破。在本文涉及的领域，我们概述了Axicabagene cilolucel与目前批准的药物以及其他正在研究的CAR T细胞和T细胞重定向疗法治疗复发或难治性滤泡性淋巴瘤的药物概况。我们还回顾了Zuma-5 II期试验的有效性、安全性和药代动力学数据，这形成了最近批准Axicabagene cilolucel的基础。专家认为，Axicabagene cilolucel是第一种被批准用于复发或难治性滤泡性淋巴瘤的细胞疗法，在经过大量预治疗的患者中显示出高的持久应答率和可控的毒性。
Introduction Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an anti-CD20 monoclonal antibody with an alkylating agent, providing a therapeutic breakthrough in a subset of indolent non-Hodgkin lymphoma associated with poor clinical outcomes. Areas covered In this article, we outline the drug profile of axicabtagene ciloleucel in comparison to currently approved agents and other CAR T-cell and T-cell redirecting therapies under investigation for the treatment of relapsed or refractory follicular lymphoma. We also review the efficacy, safety, and pharmacokinetic data from the ZUMA-5 phase II trial, which forms the basis of the recent approval of axicabtagene ciloleucel. Expert opinion Axicabtagene ciloleucel is the first cellular therapy approved for relapsed or refractory follicular lymphoma, demonstrating high rates of durable responses and a manageable toxicity profile in heavily pre-treated patients.